Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Commission Reconsiders Eudamed Deadlines And Delays ‘Actor’ Registration

Executive Summary

Voluntary “actor” registration under version 3 of the new Eudamed database, a vital cornerstone of the Medical Device Regulation, will not take place this May as had been planned.

You may also be interested in...

Eudamed: Four Modules Due To Come Online By Mid-2021

The medtech sector is getting impatient with the European Commission’s frequent changes in the launch date for the new Eudamed medical device database, a foundation stone for the new regulations. The commission has just announced an ambitious new timetable.

Eudamed Timelines: Unraveling Contradictory Legislation To Understand How The Deadlines Apply – A Lawyer’s View

The new version of the Eudamed database has been delayed – the European Commission says by two years. But how extensive is the delay? Fieldfisher partner, Alison Dennis, explains why the medtech sector needs to be cautious about how it interprets the latest developments.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts